Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry

Simple item page
dc.contributor.authorBodur H.
dc.contributor.authorYurdakul F.G.
dc.contributor.authorAtaman S.
dc.contributor.authorCay H.F.
dc.contributor.authorGurer G.
dc.contributor.authorCapkin E.
dc.contributor.authorSezer İ.
dc.contributor.authorDuruoz M.T.
dc.contributor.authorMelikoglu M.A.
dc.contributor.authorRezvani A.
dc.contributor.authorYagci I.
dc.contributor.authorGogus F.
dc.contributor.authorKamanli A.
dc.contributor.authorAkgul O.
dc.contributor.authorCevik R.
dc.date.accessioned2024-07-22T08:04:21Z
dc.date.available2024-07-22T08:04:21Z
dc.date.issued2022
dc.description.abstractObjectives: Factors associated with disease activity of axial spondyloarthritis (axSpA) and switching of biologic disease-modifying anti-rheumatic drugs have not been clearly defined. We aimed to evaluate clinical characteristics of patients with axSpA, factors related to remission in treat to target era and predictive factors for biologic disease-modifying anti-rheumatic drug switching. Method: A multicenter, observational cross-sectional study was performed between February 2019 and August 2019. We included all consecutive patients ≥ 18 years with axSpA. Demographic and clinical variables were prospectively recorded. Clinical tools included Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Metrology Index (BASMI), and Maastricht Ankylosing Spondylitis Enthesitis Score (MASES). Results: There were 969 patients with a mean age of 43.4 ± 10.8 years. There were 143 patients (14.8%) with remission and 223 (23.1%) patients with low disease activity. Male sex (p = 0.021), positive family history (p = 0.036), and human leukocyte antigen-B27 (p = 0.011) were predictors of remission by ASDAS-CRP. There were 654 patients (67.5%) who did not switch to another drug. The highest BASMI and MASES scores were calculated in patients with very high disease activity (p < 0.05). In patients with drug switching, the disease duration was significantly higher (p < 0.001) and the age at diagnosis was significantly lower (p = 0.016). There were significantly more patients with uveitis and higher scores of MASES and BASMI in patients who switch to another biologic disease-modifying anti-rheumatic drugs (p = 0.003, p = 0.009, and p = 0.004, respectively). Conclusions: In patients with axSpA, male sex, younger age, and HLA-B27 positivity are associated with remission, while longer disease duration and accompanied uveitis appear to be related with drug switching. Clinical trial registration number and date: NCT04139954/25.10.2019. © 2022, The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
dc.identifier.DOI-ID10.1007/s10067-022-06145-8
dc.identifier.issn07703198
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12670
dc.language.isoEnglish
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.subjectAdult
dc.subjectAntirheumatic Agents
dc.subjectAxial Spondyloarthritis
dc.subjectBiological Products
dc.subjectC-Reactive Protein
dc.subjectCross-Sectional Studies
dc.subjectDrug Substitution
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRegistries
dc.subjectSeverity of Illness Index
dc.subjectSpondylarthritis
dc.subjectSpondylitis, Ankylosing
dc.subjectadalimumab
dc.subjectcorticosteroid
dc.subjectdisease modifying antirheumatic drug
dc.subjectetanercept
dc.subjectgolimumab
dc.subjectHLA B27 antigen
dc.subjectnonsteroid antiinflammatory agent
dc.subjectantirheumatic agent
dc.subjectbiological product
dc.subjectC reactive protein
dc.subjectadult
dc.subjectAnkylosing Spondylitis Disease Activity Score
dc.subjectArticle
dc.subjectaxial spondyloarthritis
dc.subjectBath ankylosing spondylitis disease activity index
dc.subjectBath Ankylosing Spondylitis Metrology Index
dc.subjectcontrolled study
dc.subjectcross-sectional study
dc.subjectdemographics
dc.subjectdrug substitution
dc.subjectfamily history
dc.subjectfemale
dc.subjecthuman
dc.subjectMaastricht Ankylosing Spondylitis Enthesitis Score
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectmusculoskeletal disease assessment
dc.subjectobservational study
dc.subjectremission
dc.subjectuveitis
dc.subjectankylosing spondylitis
dc.subjectclinical trial
dc.subjectdrug substitution
dc.subjectmiddle aged
dc.subjectregister
dc.subjectseverity of illness index
dc.subjectspondylarthritis
dc.titleWhere we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry
dc.typeArticle

Files

Collections

Scopus Koleksiyonu